Corporate Update

Positive Results for MaaT013 From Phase 2 Clinical Trial and Early Access Program

Webcast December, 13 2021

Disclaimer

This document has been prepared by MaaT Pharma (the "**Company**") and is for information and background purposes only.

While the information contained herein has been prepared in good faith, neither the Company, nor its shareholders, directors, officers, agents, employees, or advisors give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the fairness, accuracy, reliability or completeness of the information in this document, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers, including financial information (all such information being referred to as "**Information**"), and liability therefor is expressly disclaimed. Accordingly, neither the Company nor any of its shareholders, directors, officers, agents, employees, affiliates, representatives or advisers take any responsibility for, or will accept any liability whether direct or indirect express or implied, contractual, tortuous, statutory or otherwise, in respect of the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising from this document.

The information and opinions contained in this document are provided as of the date of this document only and may be updated, supplemented, revised, verified or amended, and thus such information may be subject to significant changes. The Company is not under any obligation to update the information or opinions contained herein which are subject to change without prior notice.

The information contained in this document has not been subject to independent verification and are qualified in their entirety by the business, financial and other information that the Company is required to publish in accordance with the rules, regulations and practices applicable to companies listed on the regulated market of Euronext in Paris, including in particular the risk factors and other information in the Company's Document d'enregistrement (Registration Document) registered by the French *Autorité des marches financiers* (Financial Markets Authority) (the "**AMF**") on October 1st, 2021 under no. I.21-0057 and its supplement on October 14, 2021 under no. I.21-0061 and in any other periodic report, which are available free of charge on the websites of the Company (https://www.maatpharma.com/) and the AMF (www.amf-france.org).

No representation, warranty or undertaking, express or implied, is made as to the accuracy, completeness or appropriateness of the information and opinions contained in this document. The Company, its subsidiaries, its advisors and representatives accept no responsibility for and shall not be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained herein.

This document contains information on the Company's markets and competitive position, and more specifically, on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisers concerning any evaluation of the Company and its prospects, and this document, or any part of it, may not form the basis of or be relied on in connection with any investment decision.

This document contains certain forward-looking statements. These statements are not guarantees of the Company's future performance. These forward-looking statements relate to the Company's future prospects, developments and marketing strategy and are based on analyses of earnings forecasts and estimates of amounts not yet determinable.

Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Company's future performance and the Company's actual financial position, results and cash flow, as well as the trends in the sector in which the Company operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Even if the Company's financial position, results, cash-flows and developments in the sector in which the Company operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Company's future results or developments. The Company does not undertake any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document.

All persons accessing this document are deemed to agree to all the limitations and restrictions set out above.

Speakers

Hervé Affagard

Co-founder and CEO

Dr. John Weinberg

Chief Medical Officer

Pr. Mohamad Mohty

Professor - Sorbonne University
Head of the Clinical Hematology and Cellular Department - Saint-Antoine Hospital

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

Microbiome Ecosystem Therapies in Oncology

Hervé Affagard

Co-founder and CEO

Host – Microbiota Interactions are Critical for a Functional Immune System



Cross-section of a healthy gut

- A rich and diversified gut ecosystem actively modulates the immune system functionality
- A diversified microbiome contributes to the education and modulation of our immune system throughout life
- Bacterial richness and mucus layer prevent colonization by pathogens and improve gut barrier
- 80% of cellular host defense are localized in the gut (including innate and adaptive systems)

Diversity matters!
Higher gut microbiome diversity is associated with …

Liquid Tumors

Higher survival rate in patients receiving allo-HSCT *,1



Lower incidence and lower mortality from aGvHD*,2



-30% mortality aGvHD

Solid Tumors

Higher response rate to ICI* in patients with metastatic melanoma3



1

MaaT Pharma MET Inverse Simpson (mean): **24**

*allo-HSCT: allogeneic hematopoietic stem cell transplantation; aGvHD: acute Graft-vs-host-Disease; ICI: Immune Checkpoint Inhibitors

[1]Peled, J.U. & al N Engl J Med 2020;382:822-34; [2]Ghani, 2021 ; [2]Jenq RR. et al, Biol Blood Marrow Transplant 21 (2015) 1373e1383; Pamer, Blood, 2014 ; Gopalakrishnan et al., Science, 2017, Routy et al, Science, 2018 ; Vetizou et al Science 2015;

Cutting-edge platform generating a diversified product range

Microbiome Ecosystem Therapies (MET)

cGMP Platform

Native

MaaT013

- ✓ **High diversity**
- ✓ Full ecosystem
- ✓ **Butycore™** (anti-inflammatory)

Entering Phase 3 aGvHD

Entering Phase 2 I/O

MaaT033

Phase 1 Allo-HSCT

Co-fermented

MaaT03X

- ✓ **Indication-specific designed ecosystem** (from clinical data)
- ✓ Innovative **ecosystem co-fermentation technology**

Preclinical Solid Tumors

MaaT013 for the treatment of acute Graft-vs-host-Disease

Results from Phase 2 Clinical Trial and Early Access Program Presented at ASH 2021

Pr. Mohamad Mohty

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

An urgent medical need in acute Graft-vs-host-Disease (aGvHD)

Intestinal dysbiosis is associated with higher mortality in hemato-oncology

Chemotherapy
Antibiotics
Irradiation,
Immunosuppressors

Allogenic Hematopoietic Stem Cell Transplantation (allo-HSCT)
~ 22 000 patients/yr[1]

Steroids

MaaT013 Treatment

Patients with liquid tumors
(Leukemia, lymphoma, myeloma…)



Loss of diversity (dysbiosis)

- Infections
- Complications

Acute Graft-versus-Host Disease (aGvHD)

~ 10 000 patients/yr[1]

~ 50% steroid-resistant
~ 60% with GI symptoms
~ 70-90% 1-yr mortality

1. EU5 + US : (~ 20 500 primary procedures with an additional 7%-10% recurring)

MaaT013 aims to restore interaction between the microbiome and the immune system to treat aGvHD



Two complementary approaches generating data on MaaT013

Phase 2 clinical trial - HERACLES

- Phase 2 clinical trial HERACLES (NCT03359980)
  - N=24 patients
  - 4 countries
- Gastro-intestinal aGvHD grade III-IV
- Steroid-refractory
- 3 doses of MaaT013 as a monothérapie over 2 weeks
- 2nd line of treatment
- Follow-up at 28 days (response) and after 12 months (overall survival)

Early Access Program (ex « ATU »)

- Authorized par the French regulator (ANSM)
  - N=52 patients
  - France
- Gastro-intestinal aGvHD grade II-IV
- Steroid-refractory or steroid-dependent
- 3 doses of MaaT013 as monotherapy or in combination
- After 1 to 6 lines of treatment
- Follow-up at 28 days (response) and after 12 months (overall survival)

MaaT013 has received Orphan Drug Designation from FDA and EMA

HERACLES Phase 2 Clinical Trial
Promising results in a very severe population (grade III-IV)

- 3 doses, 2nd line
- N=24 patients
  - 96% grade III, 4% grade IV
  - 100% steroid-resistant (SR)
  - Gastrointestinal (GI) predominant
- Very good safety and tolerability profile
  - 39 adverse events reported within 24 hours of administration



HERACLES: MaaT013 increases Responders' microbiome diversity and their overall survival

Microbiota Diversity



Responders

Non-responders

MaaT013

Survival Rate



Early Access Program (EAP): A promising confirmation in a more diverse population

- 3 doses , 2nd to 7th line
- N=52 patients
  - 83% steroid-resistant (17% steroid-dependent)
  - 94% grade III, 6% grade II
  - All have gastrointestinal (GI) involvement
  - Previous treatments: 1-6 (median: 3)
    - 77% have received ruxolitinib previously
- Good tolerability and safety profile in a fragile population



Early Access Program (EAP): Very good overall survival results at 6 mo and 1 year

Overall Survival
All patients



Median of follow-up in alive patients : 361 days (63-731)

Overall Survival
Responders vs. Non responders



Next Step: ARES Phase 3 Clinical Trial

- Presented results support entering Phase 3, expected to be the last stage before registration
- **Positioned as 3rd line of treatment, to answer a strong medical need** (patients refractory to both steroids and ruxolitinib)
  - *No approved product in 3rd line to date*

- N=75 patients aGvHD grade II-IV
  - Pivotal single arm study
  - Interim results expected H2 2022



Corporate Update

Hervé Affagard

Co-founder & CEO

Value-creating milestones expected in the next 12 months, including MaaT013 entering Phase 3 clinical trial

Hemato-oncology

aGvHD
MaaT013
(pooled enema)
FDA & EMA Orphan Drug Designation

- ✓ Phase 3 ready to start in Europe
  - ✓ Authorization from 2 European countries received
  - MaaT Pharma will communicate at the inclusion of first patient (FPI)
  - Pursuit of Early Access Program in France
- Extension to US sites expected H2 2022 subject to IND approval by the FDA

Complications post allo-HSCT
MaaT033
(pooled capsule)

- ✓ Phase 1b ongoing
  - Results expected S1 2022
- Pivotal Phase 2/3 expected to start end of 2022

Immuno-oncology

Melanoma Checkpoint Inhibitors Potentiation
MaaT013
(pooled enema)

- ✓ Phase 2a ready to start in France (Sponsor AP-HP)[1]
  - ✓ Authorization from ANSM received

ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS

Solid Tumor
MaaT03X
(co-fermented capsule)

- ✓ Preclinical study ongoing
  - First clinical study expected H1 2023
  - Public grant of 4.26M€ received (France Relance-PIA4)

[1] Investigator sponsored trial where MaaT Pharma supplies the drugs and performs the microbiome profiling using its gutPrint® platform

Key differentiators of MaaT Pharma in the microbiome field

Full ecosystem approach

Pioneering a full ecosystem approach leveraging the full functionality of the microbiome

Manufacturing versatility

Capacity to industrialize manufacturing processes (cGMP) for native and co-fermented products

Oncology focus

Focus on high unmet need diseases in hemato-oncology and solid tumor spaces

Established proof of concept

Validated approach in **clinical trials authorized by multiple regulatory authorities**

Q&A

Hervé Affagard

Prof. Mohamad Mohty

Dr. John Weinberg



THANK YOU